PL1641456T3 - Gaboksadol do leczenia depresji i innych zaburzeń afektywnych - Google Patents
Gaboksadol do leczenia depresji i innych zaburzeń afektywnychInfo
- Publication number
- PL1641456T3 PL1641456T3 PL04738956T PL04738956T PL1641456T3 PL 1641456 T3 PL1641456 T3 PL 1641456T3 PL 04738956 T PL04738956 T PL 04738956T PL 04738956 T PL04738956 T PL 04738956T PL 1641456 T3 PL1641456 T3 PL 1641456T3
- Authority
- PL
- Poland
- Prior art keywords
- gaboxadol
- treating depression
- affective disorders
- pharmaceutical composition
- relates
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 3
- 229950004346 gaboxadol Drugs 0.000 title abstract 3
- 208000019022 Mood disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48301903P | 2003-06-25 | 2003-06-25 | |
| DKPA200300956 | 2003-06-25 | ||
| US53512304P | 2004-01-07 | 2004-01-07 | |
| DKPA200400016 | 2004-01-07 | ||
| PCT/DK2004/000459 WO2004112786A2 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
| EP04738956A EP1641456B1 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1641456T3 true PL1641456T3 (pl) | 2010-08-31 |
Family
ID=33545397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04738956T PL1641456T3 (pl) | 2003-06-25 | 2004-06-25 | Gaboksadol do leczenia depresji i innych zaburzeń afektywnych |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP2145620A3 (pl) |
| JP (1) | JP2007508236A (pl) |
| AT (1) | ATE459353T1 (pl) |
| AU (1) | AU2004248890A1 (pl) |
| BR (1) | BRPI0410857A (pl) |
| CY (1) | CY1110046T1 (pl) |
| DE (1) | DE602004025808D1 (pl) |
| DK (1) | DK1641456T3 (pl) |
| ES (1) | ES2341004T3 (pl) |
| HR (1) | HRP20100276T1 (pl) |
| IL (2) | IL172631A0 (pl) |
| MX (1) | MXPA05013016A (pl) |
| NZ (1) | NZ543586A (pl) |
| PL (1) | PL1641456T3 (pl) |
| PT (1) | PT1641456E (pl) |
| SI (1) | SI1641456T1 (pl) |
| WO (1) | WO2004112786A2 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023256A1 (en) * | 2003-09-10 | 2005-03-17 | Merck Sharp & Dohme Limited | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| EP2343073A3 (en) | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| EP1742624B1 (en) | 2004-02-18 | 2010-01-06 | Sepracor, Inc. | Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP2292222A1 (en) | 2005-01-28 | 2011-03-09 | H. Lundbeck A/S | Polymorphic Forms of a GABAA Agonist |
| WO2006118897A1 (en) * | 2005-04-29 | 2006-11-09 | H.Lundbeck A/S | Acid and base salt forms of gaboxadol |
| TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| JP2012501301A (ja) * | 2008-09-01 | 2012-01-19 | ハー・ルンドベック・アクチエゼルスカベット | ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物 |
| WO2016150953A1 (en) | 2015-03-24 | 2016-09-29 | H. Lundbeck A/S | Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol |
| AU2016295138B2 (en) | 2015-07-17 | 2021-11-04 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| CA3095682A1 (en) * | 2018-04-06 | 2019-10-10 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of substance use disorders |
| WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| CN114072154B (zh) * | 2018-11-21 | 2024-03-08 | 塞迪戈Abc有限责任公司 | 用于治疗精神障碍的加波沙朵和锂的组合物 |
| MX2021005992A (es) * | 2018-11-21 | 2021-09-14 | Certego Therapeutics Inc | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
| JP2022514275A (ja) | 2018-12-17 | 2022-02-10 | オービッド・セラピューティクス・インコーポレイテッド | 非２４時間型睡眠覚醒障害の処置のためのガボキサドールの使用 |
| MX2022007715A (es) | 2019-12-18 | 2022-07-19 | Ovid Therapeutics Inc | Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| AU2002338855B2 (en) | 2001-05-21 | 2007-08-16 | H. Lundbeck A/S | Granular preparations of gaboxadol |
-
2004
- 2004-06-25 MX MXPA05013016A patent/MXPA05013016A/es active IP Right Grant
- 2004-06-25 JP JP2006515735A patent/JP2007508236A/ja active Pending
- 2004-06-25 DK DK04738956.4T patent/DK1641456T3/da active
- 2004-06-25 PL PL04738956T patent/PL1641456T3/pl unknown
- 2004-06-25 ES ES04738956T patent/ES2341004T3/es not_active Expired - Lifetime
- 2004-06-25 EP EP09173892A patent/EP2145620A3/en not_active Withdrawn
- 2004-06-25 DE DE602004025808T patent/DE602004025808D1/de not_active Expired - Lifetime
- 2004-06-25 AU AU2004248890A patent/AU2004248890A1/en not_active Abandoned
- 2004-06-25 SI SI200431414T patent/SI1641456T1/sl unknown
- 2004-06-25 EP EP04738956A patent/EP1641456B1/en not_active Expired - Lifetime
- 2004-06-25 WO PCT/DK2004/000459 patent/WO2004112786A2/en not_active Ceased
- 2004-06-25 AT AT04738956T patent/ATE459353T1/de not_active IP Right Cessation
- 2004-06-25 NZ NZ543586A patent/NZ543586A/en unknown
- 2004-06-25 HR HR20100276T patent/HRP20100276T1/hr unknown
- 2004-06-25 PT PT04738956T patent/PT1641456E/pt unknown
- 2004-06-25 BR BRPI0410857-4A patent/BRPI0410857A/pt not_active IP Right Cessation
-
2005
- 2005-12-15 IL IL172631A patent/IL172631A0/en unknown
-
2009
- 2009-11-12 IL IL202106A patent/IL202106A0/en unknown
-
2010
- 2010-05-14 CY CY20101100433T patent/CY1110046T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL202106A0 (en) | 2010-06-16 |
| BRPI0410857A (pt) | 2006-07-04 |
| WO2004112786A3 (en) | 2005-04-14 |
| NZ543586A (en) | 2009-07-31 |
| DE602004025808D1 (de) | 2010-04-15 |
| JP2007508236A (ja) | 2007-04-05 |
| HRP20100276T1 (hr) | 2010-06-30 |
| AU2004248890A1 (en) | 2004-12-29 |
| MXPA05013016A (es) | 2006-03-02 |
| ES2341004T3 (es) | 2010-06-14 |
| PT1641456E (pt) | 2010-06-01 |
| CY1110046T1 (el) | 2015-01-14 |
| EP1641456B1 (en) | 2010-03-03 |
| WO2004112786A2 (en) | 2004-12-29 |
| EP2145620A3 (en) | 2010-03-17 |
| EP2145620A2 (en) | 2010-01-20 |
| DK1641456T3 (da) | 2010-06-21 |
| ATE459353T1 (de) | 2010-03-15 |
| SI1641456T1 (sl) | 2010-06-30 |
| EP1641456A2 (en) | 2006-04-05 |
| IL172631A0 (en) | 2006-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL202106A0 (en) | Gaboxadol for treating depression and other affective disorders | |
| ECSP10010007A (es) | Tratamiento con ligandos alpha-7-selectivos | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| TW200612892A (en) | Novel compounds | |
| WO2004047830A3 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen | |
| PT2050447T (pt) | Forma de dosagem oral contendo entacapona | |
| TW200732296A (en) | Novel compounds | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| MX2009002842A (es) | Inhibidores heterociclicos de c-met y usos de los mismos. | |
| CL2008003231A1 (es) | Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura. | |
| SE0401465D0 (sv) | New substituted piperdines as modulators of dopamine neurotransmission | |
| MY143241A (en) | 3, 5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission | |
| WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions | |
| UA90656C2 (ru) | Габоксадол для лечения депрессии | |
| MX2007006042A (es) | Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion. | |
| MEP1908A (xx) | Gabaksadol za liječenje depresije i drugih afektivnih poremećaja | |
| WO2009158387A3 (en) | Compositions, formulations, and methods for preventing and/or treating physical effects of alcohol consumption | |
| WO2004098519A3 (en) | Ginkgo biloba extract as a treatment for therapeutic induced neurotoxicity | |
| BRPI0520199A2 (pt) | acelerador de recalcificaÇço de esmalte dentÁrio e composiÇço oral e alimento ou bebida que contÊm essa composiÇço | |
| WO2007121883A3 (de) | 1,4:3,6-dianhydromannitol-derivate und deren verwendung | |
| WO2011008675A3 (en) | Catecholamine compounds, compositions, and formulations, and methods of using the same | |
| MX2010004422A (es) | Compuestos de 2,3-dihidro-benzofurano. | |
| CL2009001113A1 (es) | Compuestos derivados de 4,5-diarilpirrol-2-carboxamida; procedimiento de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento y/o prevencion de trastornos psiquiatricos, dependencia a sustancias, entre otras. | |
| DK1631298T3 (da) | Glykosaminoglykaner til behandling af emotionelle funktionsforstyrrelser | |
| MXPA06013945A (es) | Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina. |